Catalent Greenville, Inc.

The purpose of this study was to evaluate the effectiveness of elacestrant therapy in the Chinese population, as measured by blinded independent review committee (BIRC)-assessed progression-free survival (BIRC-PFS), compared with standard of care (SoC) [fulvestrant or aromatase inhibitor (AI)] in postmenopausal Chinese women or men with advanced breast cancer who were estrogen receptor (ER)-positive (ER+), human epidermal growth factor receptor-2 (HER2)-negative (HER2-), or had estrogen receptor 1 (ESR1) mutations and had received 1 or 2 lines of endocrine therapy.

To evaluate the safety and efficacy of Bomedemstat (MK-3543/IMG-7289) compared with best available therapy (BAT) in subjects with essential thrombocythemia who are inadequately responded to or intolerant of hydroxyurea

To evaluate the efficacy of AK0901 compared with placebo in pediatric subjects aged 6-12 years with ADHD. To evaluate the safety and tolerability of AK0901 compared with placebo in pediatric subjects aged 6-12 years with ADHD.